Skip to main content
. 2018 Apr 5;126(4):047002. doi: 10.1289/EHP1575

Figure 1.

Figure 1A represents the dosing regimen timeline and two bar graphs showing body weight in grams and uterine to body weight ratio on the fifth postnatal day for control mice and mice treated with genistein. Figures 1B and 1C represent the bar graphs plotting the relative mRNA expression (y-axis) of Ppib, Gilz, Fkbp5, Sgk1, Klf13, Per1, 11βhsdII, and Il13ra2 for control and genistein-treated mice (x-axis), where 1B is relative expression at baseline and 1c is relative expression in response to dexamethasone treatment.

Effect of neonatal genistein exposure on immediate glucocorticoid target gene expression. (A) Schematic representation of dosing schedule and experimental end points. Body and uterine weights (g) were determined on PND5 for control and genistein-treated mice. Data represent mean of 6–7 mice±SEM. ** p<0.01 determined by Student’s t-test. (B and C) Relative mRNA expression of Ppib, Gilz, Fkbp5, Sgk1, Klf13, Per1, 11βhsdII, and Il13ra2 as measured by qRT-PCR 4 h following subcutaneous injection of vehicle or 1mg/kg Dex on PND5. (B) Basal gene expression was determined by comparing the vehicle-treated genistein group to vehicle-treated controls. (C) Fold change was determined by reporting values relative to vehicle-treated controls. Values are normalized to the reference gene peptidylprolyl isomerase B (Ppib). Bar graphs show the mean±SEM from 3 to 5 animals. ** p<0.01 as determined by ANOVA with Tukey’s post hoc analysis. Dex, dexamethasone; PND, postnatal day; qRT-PCR, quantitative real-time polymerase chain reaction; Treat, treatment; Veh, vehicle.